Microdose Psychedelic Insights

Shifting the world's perception of psychedelic medicine.
News ⤵️

[Microdose Psychedelic Insights @MicrodoseHQ]

We sat down with Scotch McClure of @MaxwellBiosci to talk about disease prevention, reversing aging, and the future of health. This interview will change how you think about aging: https://t.co/C99cGYA1e8

[Microdose Psychedelic Insights @MicrodoseHQ]

Synthetic immune systems could be the next big breakthrough in biotech. Hear from Scotch McClure, CEO of @MaxwellBiosci, on how they're leading the charge. Watch now: https://t.co/C99cGYAz3G

[Microdose Psychedelic Insights @MicrodoseHQ]

The future of health might lie in our microbiome. Learn how Scotch McClure and @MaxwellBiosci are unlocking the secrets to a longer, healthier life https://t.co/C99cGYAz3G

[Microdose Psychedelic Insights @MicrodoseHQ]

What if we could replace antibiotics and antivirals with one solution? Scotch McClure from @MaxwellBiosci explores this exciting future in our latest interview: https://t.co/C99cGYA1e8

[Microdose Psychedelic Insights @MicrodoseHQ]

Is reversing aging the next big biotech breakthrough? Hear from Scotch McClure, CEO of @MaxwellBiosci, on how their research could transform health and longevity. https://t.co/C99cGYA1e8

[Microdose Psychedelic Insights @MicrodoseHQ]

Imagine a world where aging is reversible. CEO Scotch McClure explains how @MaxwellBiosci is pushing the boundaries of science to make it happen. Watch the full interview here: https://t.co/C99cGYAz3G

[Microdose Psychedelic Insights @MicrodoseHQ]

Scotch McClure from @MaxwellBiosci discusses reversing aging, pathogen-fighting peptides, and their implications for human health in our latest interview: https://t.co/C99cGYAz3G

[Microdose Psychedelic Insights @MicrodoseHQ]

Is aging contagious? Our latest interview with Scotch McClure, CEO of @MaxwellBiosci, explores groundbreaking theories that could reshape how we think about aging and health. Watch now on our website https://t.co/C99cGYA1e8

[Microdose Psychedelic Insights @MicrodoseHQ]

In a powerful interview with @BostonMagazine, actress @elizadushku shares her transformative journey with psychedelic-assisted therapy: https://t.co/d7qV2TRSJH

[Microdose Psychedelic Insights @MicrodoseHQ]

Mindstate Design Labs AI-Designed Trial Gets FDA Approval

Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001.

https://t.co/ELHtCCOJ6z

[Microdose Psychedelic Insights @MicrodoseHQ]

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics

Clairvoyant is running a Phase IIb clinical trial evaluating synthetic psilocybin for Alcohol Use Disorder (AUD)

https://t.co/AW3p9LKYgx

[Microdose Psychedelic Insights @MicrodoseHQ]

The FDA panel has rejected the first MDMA treatment for PTSD, citing serious concerns about the quality and reliability of the clinical trials conducted.

https://t.co/u2VWCLImzW

[Microdose Psychedelic Insights @MicrodoseHQ]

We recently sat down with @neonneurons, CEO of @TerranBio, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. Read the full interview here: https://t.co/eYZPsvqL3b

[Microdose Psychedelic Insights @MicrodoseHQ]

In a new study, researchers from the Centre for Psychedelic Research at @imperialcollege found that on average, people reported improvements across a range of areas of sexual function up to six months after their psychedelic experience, including their enjoyment of sex, sexual arousal, satisfaction with sex, attraction to partner, their own physical appearance, communication, and their sense of connection.

https://t.co/FHDCQukeY6

[Microdose Psychedelic Insights @MicrodoseHQ]

Big News as MAPS PBC Rebrands to Lykos Therapeutics; Closes $100m Series A Funding

https://t.co/MsZdQvLK8J

[Microdose Psychedelic Insights @MicrodoseHQ]

Atai Life Sciences Invests $50 Million into Beckley Psytech.

The investment gives atai a 35.5% ownership share and exposure to Beckley's advanced trials.

https://t.co/l9cMeUl181

[Beckley Psytech @BeckleyPsytech]

We’re proud to share that we’ve received a strategic investment from @atai_life to scale our clinical pipeline of novel, effective, fast-acting psychedelic compounds. Click here to find out more: https://t.co/BNrQNjW5b0

[Microdose Psychedelic Insights @MicrodoseHQ]

Microdose takes a look at the top psychedelic stories of 2023. Including:

- Australia Legalization
- Government Support for Psychedelics
- MindMed's Phase 2b LSD Trial
- Cybin's Phase 2 Trials for Depression
- MAPS New Drug Application With FDA

https://t.co/seWQzH6h3U

[Microdose Psychedelic Insights @MicrodoseHQ]

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history

https://t.co/Our5Ozkfp8

[Microdose Psychedelic Insights @MicrodoseHQ]

Awakn signs global licensing agreement for exclusivity of proprietary S-ketamine oral film formulation $AWKN
https://t.co/yFSjcaS5Iy

[Microdose Psychedelic Insights @MicrodoseHQ]

Terran Biosciences Receives FDA Clearance for MRI Scan Technology

Terran gets FDA approval for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI

https://t.co/ahgk5Ka13s